Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis

Godding, Linda T.H. ; Seyger, Marieke M.B. ; Duvetorp, Albert LU orcid ; Otero, Marisol E. ; Ossenkoppele, Paul M. ; Oostveen, Annet M. ; Visch, M. Birgitte ; Van Der Voort, Ella A.M. ; Körver, John E.M. and Weppner-Parren, Lizelotte J.M.T. , et al. (2025) In Acta Dermato-Venereologica 105.
Abstract

Although biologics have revolutionized psoriasis treatment, they pose a significant burden on the healthcare budget. With the wide range of biologics available and the increasing number of biosimilars, insights into the real-world cost per responder (CPR) are required. Therefore, this study aims to evaluate the real-world CPR of adalimumab, ustekinumab, IL17-and IL23-inhibitors, incorporating both relative (Psoriasis Area and Severity Index; PASI75/90/100) and absolute (PASI ≤ 3/ ≤ 1) responder definitions and real-world dose adjustments. Tildrakizumab and bimekizumab were excluded due to limited data. Using Dutch list prices and discounts on adalimumab’s and ustekinumab’s originator prices because of biosimilar availability, adalimumab... (More)

Although biologics have revolutionized psoriasis treatment, they pose a significant burden on the healthcare budget. With the wide range of biologics available and the increasing number of biosimilars, insights into the real-world cost per responder (CPR) are required. Therefore, this study aims to evaluate the real-world CPR of adalimumab, ustekinumab, IL17-and IL23-inhibitors, incorporating both relative (Psoriasis Area and Severity Index; PASI75/90/100) and absolute (PASI ≤ 3/ ≤ 1) responder definitions and real-world dose adjustments. Tildrakizumab and bimekizumab were excluded due to limited data. Using Dutch list prices and discounts on adalimumab’s and ustekinumab’s originator prices because of biosimilar availability, adalimumab showed the lowest 1-year CPR across all responder definitions. Among biologics without bio-similar availability, the lowest CPRs were seen for brodalumab and guselkumab. Overall, the cost-per-PASI ≤ 3-responder was, across all biologics, more homogeneous than the CPR based on relative PASIs. Similar patterns were seen when using Swedish prices, which are, in contrast to Dutch prices, transparent. The relevance of using real-world data, specifically with the use of absolute PASIs instead of relative PASIs, is shown in this study. Additionally, as price fluctuations have the biggest impact on cost-effectiveness, price transparency is essential to effectively guide physicians in selecting a cost-effective treatment strategy.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
biologics, cost per responder, cost-effectiveness, observational studies, psoriasis, real-world evidence
in
Acta Dermato-Venereologica
volume
105
article number
adv42767
publisher
Medical Journals Limited
external identifiers
  • pmid:40534202
  • scopus:105009207453
ISSN
0001-5555
DOI
10.2340/actadv.v105.42767
language
English
LU publication?
yes
id
c1f0535c-4b93-4399-8f3e-990a725c537b
date added to LUP
2026-01-20 17:26:44
date last changed
2026-01-21 03:37:11
@article{c1f0535c-4b93-4399-8f3e-990a725c537b,
  abstract     = {{<p>Although biologics have revolutionized psoriasis treatment, they pose a significant burden on the healthcare budget. With the wide range of biologics available and the increasing number of biosimilars, insights into the real-world cost per responder (CPR) are required. Therefore, this study aims to evaluate the real-world CPR of adalimumab, ustekinumab, IL17-and IL23-inhibitors, incorporating both relative (Psoriasis Area and Severity Index; PASI75/90/100) and absolute (PASI ≤ 3/ ≤ 1) responder definitions and real-world dose adjustments. Tildrakizumab and bimekizumab were excluded due to limited data. Using Dutch list prices and discounts on adalimumab’s and ustekinumab’s originator prices because of biosimilar availability, adalimumab showed the lowest 1-year CPR across all responder definitions. Among biologics without bio-similar availability, the lowest CPRs were seen for brodalumab and guselkumab. Overall, the cost-per-PASI ≤ 3-responder was, across all biologics, more homogeneous than the CPR based on relative PASIs. Similar patterns were seen when using Swedish prices, which are, in contrast to Dutch prices, transparent. The relevance of using real-world data, specifically with the use of absolute PASIs instead of relative PASIs, is shown in this study. Additionally, as price fluctuations have the biggest impact on cost-effectiveness, price transparency is essential to effectively guide physicians in selecting a cost-effective treatment strategy.</p>}},
  author       = {{Godding, Linda T.H. and Seyger, Marieke M.B. and Duvetorp, Albert and Otero, Marisol E. and Ossenkoppele, Paul M. and Oostveen, Annet M. and Visch, M. Birgitte and Van Der Voort, Ella A.M. and Körver, John E.M. and Weppner-Parren, Lizelotte J.M.T. and Berends, Maartje A.M. and Arnold, W. Peter and Dodemont, Sharon R.P. and Kuijpers, Astrid L.A. and Mommers, Johannes M. and Homan, Femke M. and Gostynski, Antoni H. and Velstra, Berit and Kleinpenning, Marloes M. and VAN DOORN, Martijn B.A. and Keijsers, Romy R.M.C. and Kop, Else N. and Haeck, Inge M. and Hendricksen-Roelofzen, Judith H.J. and Vellinga, Douwe and De Jong, Elke M.G.J. and Van Den Reek, Juul M.P.A.}},
  issn         = {{0001-5555}},
  keywords     = {{biologics; cost per responder; cost-effectiveness; observational studies; psoriasis; real-world evidence}},
  language     = {{eng}},
  publisher    = {{Medical Journals Limited}},
  series       = {{Acta Dermato-Venereologica}},
  title        = {{Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis}},
  url          = {{http://dx.doi.org/10.2340/actadv.v105.42767}},
  doi          = {{10.2340/actadv.v105.42767}},
  volume       = {{105}},
  year         = {{2025}},
}